Arbutus Biopharma Corporation Common Stock

ABUSNASDAQ • USD
4.09 USD
↗ 0.06 (1.49%)🔴AT CLOSE (AS OF 04:14 PM EST)
🔴Market: CLOSED

ABUS is currently priced at $4.09. The stock presents a bearish profile across the board: technical indicators signal "Sell" and our fundamental models agree with a "Sell" rating. This is driven by a concerning Altman Z-Score in the distress zone, exceptional Return on Equity (256.4%) and a bearish Death Cross on the long-term moving averages. Valuation metrics suggest ABUS is trading at a discount to its peers, earning an "Attractively Valued" rating.

Technical & fundamental data as of Nov 13, 2026.

Open?$4.04
High?$4.14
Low?$3.92
Prev. Close?$4.03
Volume?3.3M
Avg. Volume?3.0M
VWAP?$4.08
Rel. Volume?1.09x
Bid / Ask
Bid?$3.98 × 1.0K
Ask?$4.19 × 1.0K
Spread?$0.21
Midpoint?$4.09
Valuation & Ratios
Market Cap?627.0M
Shares Out?153.3M
Float?122.1M
Float %?79.7%
P/E Ratio?2.85
P/B Ratio?7.31
EPS?$1.43
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Employees
19
Market Cap
627.0M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2007-07-26
Address
701 VETERANS CIRCLE
WARMINSTER, PA 18974
Phone: 604-419-3200
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
23
Z-Score?
1
Momentum?
71
Short Sent.?
55
Piotroski F-Score?3/9Weak
Altman Z-Score?-0.98Distress
Confidence?55%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?16.28%High
Short Interest?19.9M
Days to Cover?9.1
Free Float122.1M
Avg Daily Volume2.2M
Settlement Date2026-10-30
Financial Health
Current Ratio?1.40Adequate
Quick Ratio?1.40Adequate
Cash Ratio?1.09Strong
Debt/Equity?0.03Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
89/100
P/E?
Peers
100
S&P
97
2.9CHEAP▾
P/B?
Peers
100
S&P
26
7.31FAIR▾
P/S?
Peers
100
S&P
45
3.45FAIR▾
P/FCF?
Peers
100
S&P
97
2.8CHEAP▾
EV/EBITDA?
Peers
100
S&P
97
2.5CHEAP▾
EV/Sales?
Peers
100
S&P
74
2.02CHEAP▾
Returns & Efficiency
ROE?
Peers
50
S&P
97
256.4%STRONG▾
ROA?
Peers
50
S&P
97
64.7%STRONG▾
Cash Flow & Enterprise
FCF?$221.0M
Enterprise Value?$365.8M
Fundamentals ratios updated end of day